TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates

Company Performance - TELA Bio, Inc. reported a quarterly loss of $0.42 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.37, and an improvement from a loss of $0.45 per share a year ago, indicating a surprise of -13.51% [1] - The company posted revenues of $18.96 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 0.75%, but showing growth from $15.05 million in the same quarter last year [2] - Over the last four quarters, TELA Bio has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - TELA Bio shares have declined approximately 54.4% since the beginning of the year, contrasting with the S&P 500's gain of 24.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $22.5 million, and for the current fiscal year, it is -$1.40 on revenues of $74.25 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which TELA Bio belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of TELA Bio's stock may be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than a factor of 2 to 1 [8]